Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug

Launched by BOEHRINGER INGELHEIM · May 2, 2022

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants ≥ 40 years of age at baseline visit
• • Patients with confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD)
• • Patients who have been on Spiriva® HandiHaler® for ≥ 6 weeks at baseline visit
• • Patients for whom a switch from Spiriva® HandiHaler® to Spiriva® Respimat® was planned prior to study inclusion. If additional inhalative COPD drugs (AICDs) are used: AICD treatment must have been stable for at least 6 weeks before study inclusion
• • Signed written informed consent form to participation
• Exclusion Criteria:
• • Patients who have contraindications to Spiriva® Respimat® according to the current prescribing information label/ summary of product characteristics (SmPC)
• • Patients who have signs of a current, acute respiratory tract infection 2 weeks prior visit 1
• • Patients for whom further follow-up will not be possible at the enrolling site during the planned observational period (of approximately 8 weeks)
• • Patients with confirmed diagnosis of only asthma
• • Patients who had \> 1 moderate to severe exacerbation(s) within the last 6 weeks prior to study inclusion
• • Patients who are pregnant or breastfeeding
• • Patients participating in an ongoing interventional study